J Comp Eff Res. 2012 Jul;1(4):359-70. doi: 10.2217/cer.12.36.
The Center for Comparative Effectiveness Research in Cancer Genomics completed a 2-year stakeholder-guided process for the prioritization of genomic tests for comparative effectiveness research studies. We sought to evaluate the effectiveness of engagement procedures in achieving project goals and to identify opportunities for future improvements.
MATERIALS & METHODS: The evaluation included an online questionnaire, one-on-one telephone interviews and facilitated discussion. Responses to the online questionnaire were tabulated for descriptive purposes, while transcripts from key informant interviews were analyzed using a directed content analysis approach.
A total of 11 out of 13 stakeholders completed both the online questionnaire and interview process, while nine participated in the facilitated discussion. Eighty-nine percent of questionnaire items received overall ratings of agree or strongly agree; 11% of responses were rated as neutral with the exception of a single rating of disagreement with an item regarding the clarity of how stakeholder input was incorporated into project decisions. Recommendations for future improvement included developing standard recruitment practices, role descriptions and processes for improved communication with clinical and comparative effectiveness research investigators.
Evaluation of the stakeholder engagement process provided constructive feedback for future improvements and should be routinely conducted to ensure maximal effectiveness of stakeholder involvement.
癌症基因组比较效价研究中心（Center for Comparative Effectiveness Research in Cancer Genomics）完成了为期两年的利益相关者指导下的基因组检测优先排序工作，旨在为比较效价研究开展提供参考。本研究旨在评估利益相关者参与流程在实现项目目标方面的有效性，并确定未来改进的机会。
评估包括在线问卷调查、一对一电话访谈和促进性讨论。在线问卷的回复仅作描述性分析，而关键知情人访谈的转录则采用定向内容分析方法进行分析。
共有 13 位利益相关者中的 11 位完成了在线问卷和访谈流程，其中 9 位参加了促进性讨论。89%的问卷项目获得了同意或强烈同意的总体评价；11%的答复被评为中立，只有一项对如何将利益相关者的意见纳入项目决策的说明清晰度表示不同意。未来改进的建议包括制定标准的招募实践、角色描述和与临床与比较效价研究研究人员进行更好沟通的流程。
利益相关者参与流程的评估为未来的改进提供了建设性的反馈，应定期进行，以确保利益相关者参与的最大有效性。
